Camille Vong

Comparisons of Analysis Methods for Proof‐of‐Concept Trials

KE Karlsson, Camille Vong, Martin Bergstrand et al. · CPT Pharmacometrics & Systems Pharmacology · 2013 · 52 citations · Full text

Pharmacotherapy, Systems Pharmacology, Stroke +18

Rapid Sample Size Calculations for a Defined Likelihood Ratio Test-Based Power in Mixed-Effects Models

Camille Vong, Martin Bergstrand, Joakim Nyberg et al. · The AAPS Journal · 2012 · 46 citations · Full text

Mixed-effects Models, Factor Analysis, Statistical Inference +2

Development of a model‐based clinical trial simulation platform to optimize the design of clinical trials for Duchenne muscular dystrophy

Karthik Lingineni, Varun Aggarwal, Juan Francisco Morales et al. · CPT Pharmacometrics & Systems Pharmacology · 2021 · 27 citations · Full text

Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy

Daniela J. Conrado, Jane Larkindale, Alexander Berg et al. · Journal of Pharmacokinetics and Pharmacodynamics · 2019 · 21 citations

Drug Repositioning, Duchenne Muscular Dystrophy, Pharmacology +7

Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis

Camille Vong, Steven W. Martin, Chenhui Deng et al. · Clinical Pharmacology in Drug Development · 2021 · 16 citations · Full text